
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is expected to see growth and profitability in the future, driven by their multi-year plan with three acts. The first act has focused on driving growth in the US market and the second act includes the launch of a new product, with strong demand and positive early feedback. The company remains conservative in their projections but has a goal to convert their US install base to the pharmacy channel for long-term revenue and profit growth, with potential risks and uncertainties to consider such as competition and challenges with new product launches.
Bears say
Tandem Diabetes Care is expected to face challenges in both growth and profitability in the coming years, as competition enters the automated insulin delivery market and the majority of the company's installed base converts to insurance coverage. Additionally, the company's reliance on the US market and disposable infusion sets may limit its potential for international expansion and diversification. With a valuation already factoring in future success, it remains to be seen if Tandem Diabetes Care can deliver sustained top-line growth and justify a higher valuation.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares